Table 1.
Characteristic | Active treatment cohort (N = 1454) |
---|---|
Gender (females, males), n (%) | 1318 (90.6), 136 (9.4) |
Age (years), mean (SD) | 70.2 (9.8) |
Body mass index (kg/m2), mean (SD) | 25.6 (4.5) |
Patients with previous fracture, n (%) | 1239 (85.2) |
Number of previous fractures, median (Q1, Q3) | 2.0 (1.0, 3.0) |
Number of previous vertebral fractures, median (Q1, Q3) | 2.0 (1.0, 3.0) |
Patients with fractures in the 12 months before starting teriparatide, n (%) | 688 (47.3) |
Patients with vertebral fractures in the 12 months before starting teriparatide, n (%) | 465 (32.0) |
Patients with maternal history of hip fracture, n (%) | 236 (19.5) |
Uses arms when standing from chair, n (%) | 756 (52.3) |
Sight problems, n (%) | 469 (32.5) |
Current smoker, n (%) | 214 (14.9) |
Exercises ≥1 h/week, n (%) | 861 (60.1) |
Hours of exercise/weeka, median (Q1, Q3) | 4.0 (2.0, 7.0) |
Has at least one alcoholic drink/week, n (%) | 507 (35.7) |
Number of patients with falls in previous year, n (%) | |
1 fall | 287 (20.5) |
>1 fall | 256 (18.2) |
Immobilised for >12 months, n (%) | 45 (3.1) |
Reproductive history for females (n = 1318)b | |
Reached menopause, n (%) | 986 (98.5) |
Years since onset of menopause, median (Q1, Q3) | 23.0 (16.0, 29.0) |
Early menopause (<40 years of age), n (%) | 70 (5.8) |
Surgical menopause, n (%) | 137 (10.9) |
Nulliparous, n (%) | 147 (11.2) |
Prior osteoporosis medication, n (%) | 1289 (88.7) |
Prior bisphosphonate use, n (%) | 941 (64.7) |
Duration of prior bisphosphonate therapy (months), mean (SD) | 20.5 (36.6) |
Current comorbidities, any disease, n (%) | 487 (33.5) |
Rheumatoid arthritis or other rheumatological disorder, n (%) | 163 (11.2) |
Taking glucocorticoids, n (%) | 210 (14.4) |
Percentages are based on patients with non-missing data
SD standard deviation, Q1, Q3 first and third quartile of interquartile range
aFor patients who reported exercising
bFifteen women were premenopausal